Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Patents (Class 424/145.1)
  • Patent number: 11155611
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 26, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Stefan Wawersik, Yung Chyung, Micah Webster
  • Patent number: 11135178
    Abstract: The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, generation, or maintenance in animals.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 5, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventor: Rajan Sah
  • Patent number: 11136402
    Abstract: This document provides antibodies against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) short, and more particularly to humanized TRAILshort antibodies that can neutralize TRAILshort. For example, materials and methods for using one or more humanized TRAILshort antibodies to induce apoptosis (e.g., via TRAIL mediated cell death, natural killer (NK) cytotoxicity, and/or CD8+ T cell killing) are provided.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 5, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Andrew D. Badley
  • Patent number: 11078270
    Abstract: The invention relates to negative functional modulators of erythropoietin (EPO) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia A and B, von Willebrand disease, angiodysplasia, proliferative disorders and neurological diseases characterized in their pathogenesis by primary neuroinflammation and/or neuroinflammation secondary to other causes. Such modulators are anti-EPO antibodies and their derivatives: anti-EPO receptor antibodies (EPOR), antisense oligonucleotides, decoy DNA, decoy RNA, ribozyme, antagomir, shRNA, LNA and/or siRNAs that inhibit the expression of the gene encoding EPO or EPOR.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 3, 2021
    Assignee: ANDREMACON S.R.L.
    Inventors: Giovanni Marfia, Stefania Elena Navone, Giuseppe Scalvini, Laura Riboni, Rolando Campanella
  • Patent number: 11066481
    Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: July 20, 2021
    Assignees: The Regents of the University of California, Pfizer, Inc.
    Inventors: Thomas Mikita, Lauren K. Ely, Huilan Gao, Yun Kim, Isaac J. Rondon, Tovo David, Shaun R. Coughlin
  • Patent number: 11059905
    Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 13, 2021
    Assignee: Prothix B.V.
    Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
  • Patent number: 11046757
    Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: June 29, 2021
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • Patent number: 11040102
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventor: Timothy David Osslund
  • Patent number: 10995365
    Abstract: Compositions, devices, systems and methods for increasing the signal to noise ratio (SNR) and/or enhancing photoprotection in an illuminated analytical reaction by addition of one or more signal detection assay (SDA)-enhancing agents to the reaction mixture.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: May 4, 2021
    Inventors: Stephen Yue, Andrei Fedorov, Gene Shen, Sophia Wu
  • Patent number: 10975168
    Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 13, 2021
    Assignee: GENENTECH, INC.
    Inventors: Shahram Misaghi, John B. Lowe, Bradley Richard Snedecor
  • Patent number: 10968282
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 6, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Patent number: 10962532
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: March 30, 2021
    Assignee: Prognosys Biosciences, Inc.
    Inventor: Mark S. Chee
  • Patent number: 10954297
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Patent number: 10954303
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOGEN MA INC.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Patent number: 10953069
    Abstract: The present disclosure provides a method for treating lung cancer in a subject in need of such treatment includes administering to the subject a pharmaceutical composition. The pharmaceutical composition includes an effective amount of a betanodavirus B2 protein or a fragment thereof, or a nucleic acid molecule encoding the betanodavirus B2 protein or the fragment and optionally a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 23, 2021
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Jiann-Ruey Hong, Hsuan-Wen Chiu, Yu-Chin Su
  • Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • Patent number: 10912605
    Abstract: A facet joint surgical tool for treating a facet joint synovial cyst includes rotatable members disposed side-by-side through a minimally invasive sheath and rotatable to reconfigure distal end portions between a facet joint penetration configuration with a tissue piercing tip and a facet joint retraction configuration. Facet joint synovial cysts located to an anterior side of the facet joint are treated by a posterior approach with access to the cyst through the facet joint retracted by the surgical tool. Facet joint synovial cysts located to a posterior side of the facet joint are treated by direct access from a posterior approach.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 9, 2021
    Assignee: Thixos LLC
    Inventors: Murray David Solsberg, Douglas Preston Beall, Ryan Erich Dean
  • Patent number: 10899827
    Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 26, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Joshua Rabbani, James J. Donegan
  • Patent number: 10882905
    Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders, in particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 5, 2021
    Assignee: AB2 BIO SA
    Inventors: Greg Del Val, Eduardo Schiffrin
  • Patent number: 10875929
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: December 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Patent number: 10858426
    Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: December 8, 2020
    Assignee: AB2 BIO SA
    Inventors: Andrea Pfeifer, Greg Del Val
  • Patent number: 10842803
    Abstract: Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: November 24, 2020
    Assignee: KRONOS BIO, INC.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Aaron C. Schmitt, Jianjun Xu, Zhongdong Zhao
  • Patent number: 10766952
    Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Rami Burstein
  • Patent number: 10758605
    Abstract: Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 1, 2020
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Nobuyuki Matoba, Keegan Baldauf, Joshua Royal
  • Patent number: 10670610
    Abstract: Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: June 2, 2020
    Assignees: Wayne State University, The United States of America as represented by The Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health, Semmelweis University, Genesis Theranostix Korlatolt Felelossegu Tarsasag
    Inventors: Adi L. Tarca, Nandor Than, Gabor Juhasz, Adrienna Katalin Kekesi, Hamutal Meiri, Zoltan Papp, Roberto Romero
  • Patent number: 10640560
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: May 5, 2020
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Patent number: 10639352
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 5, 2020
    Assignee: Chondropeptix B.V.
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Patent number: 10618962
    Abstract: The present disclosure provides antibodies and antigen binding fragments against CTLA4, which can block the binding of CTLA4 to its ligand. The antibodies of disclosure provide agents for treating diseases, such as cancer.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: April 14, 2020
    Assignee: CROWN BIOSCIENCE (TAICANG) INC.
    Inventors: Ziyong Sun, Man Zhou, Wencui Ma, Hongli Ma, Wei Chen
  • Patent number: 10611821
    Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing liver diseases, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 7, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventor: Yaron Ilan
  • Patent number: 10596296
    Abstract: A heparan sulphate that binds TGP?1 is disclosed.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 24, 2020
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon Cool, Victor Nurcombe, Jonathan Lee
  • Patent number: 10597431
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: March 24, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 10577428
    Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 3, 2020
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
  • Patent number: 10561709
    Abstract: Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: February 18, 2020
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Patent number: 10556008
    Abstract: Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: February 11, 2020
    Inventor: Randal Tanh Hoang Pham
  • Patent number: 10544231
    Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 28, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE PARIS—SUD, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE, UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2
    Inventors: Petrus Lenting, Cécile Denis, Olivier Christophe, Paulette Legendre, Antoine Rauch, Sophie Susen
  • Patent number: 10500156
    Abstract: Disclosed are multi-compartmental nanoparticulate systems for imaging as well as the diagnosis, monitoring, and treatment of inflammation and/or disease. These multicompartmental nanoparticulate systems can be used to target specific cells or cellular structures. Furthermore, these systems are capable of simultaneous delivery of hydrophilic and lipophilic compositions. Finally, these systems also allow for temporal control of drug delivery.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: December 10, 2019
    Assignee: Northeastern University
    Inventors: Mansoor M. Amiji, Mayur Kalariya, Shardool Jain, Husain Attarwala
  • Patent number: 10466252
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Patent number: 10456465
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Patent number: 10434173
    Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 8, 2019
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
  • Patent number: 10414825
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 17, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Patent number: 10400022
    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 3, 2019
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung Kim, Ye Jin Kim
  • Patent number: 10391491
    Abstract: Methods and systems for isolating platelet-associated nucleated target cells, e.g., such as circulating epithelial cells, circulating tumor cells (CTCs), circulating endothelial cells (CECs), circulating stem cells (CSCs), neutrophils, and macrophages, from sample fluids, e.g., biological fluids, such as blood, bone marrow, plural effusions, and ascites fluid, are described. The methods include obtaining a cell capture chamber including a plurality of binding moieties bound to one or more walls of the chamber, wherein the binding moieties specifically bind to platelets; flowing the sample fluid through the cell capture chamber under conditions that allow the binding moieties to bind to any platelet-associated nucleated target cells in the sample to form complexes; and separating and collecting platelet-associated nucleated target cells from the complexes.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: August 27, 2019
    Assignee: The General Hospital Corporation
    Inventors: Mehmet Toner, Shannon Stott, Eduardo Reategui, Xiaocheng Jiang
  • Patent number: 10323086
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, David Louis Shelton, Patricia Ann Walicke
  • Patent number: 10323067
    Abstract: Disclosed are peptides which specifically bind to preselected pre-miRNA or pri-miRNA targets, methods of down-regulating EMT in a cell using such peptides, and methods of preparing such peptides. Also provided are therapeutic compositions comprising peptides that specifically bind a preselected cancer marker which is a peptide or which is a pre-miRNA or a pri-miRNA and methods of treatment using the same.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 18, 2019
    Assignee: EVORX TECHNOLOGIES, INC.
    Inventors: Stephen V. Fiacco, Amanda N. Hardy, Terry T. Takahashi
  • Patent number: 10314909
    Abstract: Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: June 11, 2019
    Assignee: Dyax Corp.
    Inventor: Daniel T. Dransfield
  • Patent number: 10316083
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 11, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Patent number: 10307483
    Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 4, 2019
    Assignee: AMGEN INC.
    Inventors: Monica Goss, Nicole Ball
  • Patent number: 10302655
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Patent number: 10266607
    Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: April 23, 2019
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Dong-Sik Kim, Mi Jung Lee, Jae Chan Park, Sumin Lee, Heechun Kwak, SungHo Hwang, Hyung-Kwon Lim, Kisu Kim, Young Seoub Park, Junhong Jeong, Ki Joon Cho
  • Patent number: RE47761
    Abstract: The invention provides anti-Axl antibodies and methods of using the same.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Lin Pei, Yan Wu, Xiaofen Ye